VAD Use Beyond Sickest Patient Population Expected Soon, Experts Agree
This article was originally published in The Gray Sheet
Ventricular assist technology for patients healthier than those targeted in the pivotal REMATCH trial will be available within the next three years, Mehmet Oz, Columbia University College of Physicians and Surgeons, predicted on March 17
You may also be interested in...
Thoratec's HeartMate VE left-ventricular assist system (LVAS) should be made available to end-stage heart failure patients ineligible for a transplant, even though 94% of patients treated with the LVAS in clinical trials experienced a serious adverse event, FDA's Circulatory System Devices Panel agreed
World Heart has enrolled 28 out of 40 patients to be evaluated in the feasibility phase of its INTrEPID trial for its Novacor left ventricular assist system as an alternative-to-transplant destination therapy
Early revascularization via angioplasty or bypass surgery significantly increases the six-month survival rate of acute myocardial infarction patients with cardiogenic shock, according to a National Heart, Lung and Blood Institute study.